Traders bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Friday. $123.59 million flowed into the stock on the tick-up and $89.85 million flowed out of the stock on the tick-down, for a money net flow of $33.74 million into the stock. Of all equities tracked, Johnson & Johnson had the 19th highest net in-flow for the day. Johnson & Johnson traded down ($0.26) for the day and closed at $119.08

Several research firms have recently commented on JNJ. Royal Bank Of Canada upped their price target on Johnson & Johnson from $125.00 to $133.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 20th. BMO Capital Markets restated an “outperform” rating and set a $132.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Leerink Swann restated an “outperform” rating and set a $140.00 price target (up previously from $125.00) on shares of Johnson & Johnson in a research note on Wednesday, July 20th. RBC Capital Markets reaffirmed an “outperform” rating and set a $133.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a report on Wednesday, July 20th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a $142.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a report on Thursday, July 21st. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have issued a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $119.53.

The stock has a market cap of $326.44 billion and a P/E ratio of 22.24. The company has a 50-day moving average price of $122.43 and a 200-day moving average price of $114.84.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.06. The company earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. Analysts anticipate that Johnson & Johnson will post $6.69 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, August 19th. Shareholders of record on Friday, August 5th were given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 0.97%.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the sale, the vice president now owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Gary J. Pruden sold 9,735 shares of the business’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $116.03, for a total value of $1,129,552.05. Following the completion of the sale, the vice president now directly owns 43,630 shares of the company’s stock, valued at approximately $5,062,388.90. The disclosure for this sale can be found here.

Other institutional investors have bought and sold shares of the company. Bruni J V & Co. Co. boosted its position in Johnson & Johnson by 0.9% in the fourth quarter. Bruni J V & Co. Co. now owns 39,669 shares of the company’s stock valued at $4,075,000 after buying an additional 344 shares in the last quarter. West Chester Capital Advisors Inc. boosted its position in Johnson & Johnson by 12.6% in the fourth quarter. West Chester Capital Advisors Inc. now owns 17,746 shares of the company’s stock valued at $1,804,000 after buying an additional 1,984 shares in the last quarter. GAM Holding AG boosted its position in Johnson & Johnson by 3.0% in the fourth quarter. GAM Holding AG now owns 677,515 shares of the company’s stock valued at $69,594,000 after buying an additional 19,851 shares in the last quarter. Madison Investment Holdings Inc. boosted its position in Johnson & Johnson by 2.9% in the fourth quarter. Madison Investment Holdings Inc. now owns 603,782 shares of the company’s stock valued at $62,020,000 after buying an additional 17,287 shares in the last quarter. Finally, Mutual of America Capital Management LLC boosted its position in Johnson & Johnson by 0.4% in the fourth quarter. Mutual of America Capital Management LLC now owns 308,432 shares of the company’s stock valued at $31,682,000 after buying an additional 1,268 shares in the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.